Over the last 7 days, the United States market has risen by 1.3%, and in the past year, it has climbed an impressive 35%, with earnings forecasted to grow annually by 16%. In light of these market conditions, investors may find value in exploring penny stocks—typically smaller or newer companies that can offer unique opportunities. While the term "penny stocks" might seem outdated, they remain relevant as investment options for those seeking affordability and potential growth when backed by strong financials.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
WM Technology (MAPS)	$0.3497	$63.99M	✅ 2 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.30	$390.37M	✅ 3 ⚠️ 2 View Analysis >
FinVolution Group (FINV)	$4.69	$1.19B	✅ 4 ⚠️ 1 View Analysis >
Information Services Group (III)	$3.11	$206.43M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.74	$390.81M	✅ 3 ⚠️ 1 View Analysis >
LifeVantage (LFVN)	$4.91	$65.69M	✅ 4 ⚠️ 3 View Analysis >
Village Farms International (VFF)	$2.87	$344.16M	✅ 5 ⚠️ 1 View Analysis >
SIGA Technologies (SIGA)	$7.80	$327.41M	✅ 2 ⚠️ 1 View Analysis >
BAB (BABB)	$0.91	$6.61M	✅ 2 ⚠️ 3 View Analysis >

Let's take a closer look at a couple of our picks from the screened companies.

DocGo (DCGO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: DocGo Inc. is a mobile healthcare services company operating in the United States and the United Kingdom with a market cap of $67.44 million.

Operations: The company's revenue is derived from Mobile Health Services, generating $121.43 million, and Transportation Services, contributing $200.77 million.

Market Cap: $67.44M

DocGo Inc. presents a mixed picture for penny stock investors. While the company trades at 61% below its estimated fair value and has reduced its debt-to-equity ratio to 0.2%, it remains unprofitable with increasing losses over the past five years. Recent earnings reports showed significant declines in revenue and increased net losses, raising concerns about financial stability despite having more cash than total debt. The company faces delisting risks from Nasdaq due to not meeting the minimum bid price requirement but is exploring options like a reverse stock split to regain compliance by July 2026.

Health Catalyst (HCAT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Health Catalyst, Inc. offers data and analytics technology and services to healthcare organizations in the United States, with a market cap of approximately $92.72 million.

Operations: The company generates revenue through its Technology segment, which accounts for $208.28 million, and its Professional Services segment, contributing $102.86 million.

Market Cap: $92.72M

Health Catalyst, Inc. presents a complex scenario for penny stock investors. Despite generating US$311.14 million in revenue for 2025, the company remains unprofitable with a net loss of US$177.97 million and impairment charges of US$81.45 million impacting its financials significantly. The recent leadership change appointing Ben Albert as CEO may signal strategic shifts, yet the board's lack of experience could pose challenges. While Health Catalyst has a satisfactory net debt to equity ratio and sufficient cash runway exceeding three years, its volatile share price and negative return on equity highlight ongoing financial instability concerns amidst industry competition.

Magnachip Semiconductor (MX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Magnachip Semiconductor Corporation designs, manufactures, and supplies analog and mixed-signal semiconductor platform solutions for various applications including communications, IoT, consumer electronics, computing, industrial, and automotive sectors with a market cap of approximately $122.44 million.

Operations: The company generates revenue through its Power Solutions Business, which is divided into Power IC, contributing $18.38 million, and Power Analog Solutions, accounting for $160.48 million.

Market Cap: $122.44M

Magnachip Semiconductor's recent advancements in its 8th-generation Medium-Voltage MOSFETs showcase a strategic push into the server and high-performance computing markets, aligning with growing global demand for efficient power solutions. Despite these innovations, the company faces financial challenges, reporting a net loss of US$29.72 million for 2025 on revenues of US$178.86 million. While short-term assets comfortably cover liabilities, Magnachip remains unprofitable with declining earnings over five years at an annual rate of 60.7%. Positively, its debt to equity ratio has improved to 18%, and it maintains a sufficient cash runway exceeding one year without significant shareholder dilution recently.

Make It Happen

• Jump into our full catalog of 348 US Penny Stocks here.
• Looking For Alternative Opportunities? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.